Autologous hematopoietic cell transplantation using dose-reduced intravenous busulfan, melphalan, and thiotepa for high-risk or relapsed lymphomas

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) 2019-02, Vol.54 (2), p.330-333
Main Authors: Yoon, Jae-Ho, Min, Gi June, Park, Sung-Soo, Jeon, Young-Woo, Lee, Sung-Eun, Cho, Byung-Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Kim, Hee-Je, Min, Chang-Ki, Lee, Jong Wook, Cho, Seok-Goo
Format: Article
Language:English
Subjects:
631/67/1990/291/1621/1915
631/67/1990/291/1621/1916
96/100
Administration, Intravenous
Adolescent
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Busulfan
Busulfan - administration & dosage
Care and treatment
Cell Biology
Chemotherapy
Correspondence
Development and progression
Editors
Evidence-based medicine
Female
Hematology
Hematopoietic stem cell transplantation
Hematopoietic Stem Cell Transplantation - methods
Humans
Internal Medicine
Intravenous administration
Leukemia research
Lymphomas
Male
Medical schools
Medicine
Medicine & Public Health
Melphalan
Melphalan - administration & dosage
Methods
Middle Aged
Patient outcomes
Public Health
Recurrence (Disease)
Retrospective Studies
Salvage Therapy - methods
Stem Cells
Thiotepa - administration & dosage
Transplantation
Transplantation, Autologous
Treatment Outcome
Tumors
Universities and colleges
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0268-3369
1476-5365
DOI:10.1038/s41409-018-0289-z